Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the french perinatal cohort (EPF/ANRS CO10)

Clinical Infectious Diseases

Volumn 51, Issue 2, 2010, Pages 214-224

  Dollfus, C ^a   Le Chenadec, J ^e   Faye, A ^b   Blanche, S ^c,d   Briand, N ^e   Rouzioux, C ^c,d   Warszawski, J ^e,f,g  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSERM   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACADEMIC ACHIEVEMENT; ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; FEMALE; FOLLOW UP; FRANCE; GEOGRAPHIC ORIGIN; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERINATAL CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; REFERENCE VALUE; SCHOOL CHILD; VERTICAL TRANSMISSION; VIRUS IMMUNITY; VIRUS LOAD; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; NEWBORN; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PROCEDURES; TRANSMISSION; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LONGITUDINAL STUDIES; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77954747573     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653674     Document Type: Article

References (34)

1. The European Collaborative Study. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics 2003; 111:e52-e60.
2. Guillen S, Ramos JT, Resino R, Bellon JM, Munoz MA. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J 2007; 26:334-338.
3. Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis 2008; 46:507-515. (Pubitemid 351263487)
4. Granados JMS, Amador JTR, De Miguel FS, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus infected children. Pediatr Infect Dis J 2003; 22:863-868.
5. Ylitalo N, Brogly S, Hughes MD, et al. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Pediatr Adolesc Med 2006; 160:778-787.
6. Bertolli J, Hsu HW, Sukalac T, et al. Hospitalization trends among children and youths with perinatal human immunodeficiency virus infection, 1990-2002. Pediatr Infect Dis J 2006; 25:628-633.
7. Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45:918-924.
8. Walker AS, Doerholt K, Sharland M, Gibb DM; Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004; 18:1915-1924.
9. Scherpbier HJ, Bekker V, Van Leth F, Jurriaans S, Lange JMA, Kuijpers TW. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics 2006; 117:e528-e536.
10. Patel K, Hernan MA, Williams PL, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis 2008; 46:1751-1760.
11. Resino S, Resino R, Micheloud D, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1 infected children: 6 years of follow-up. Clin Infect Dis 2006; 42:862-869.
12. Rutstein RM, Gebo KA, Flynn PM, et al. Immunologic function and virologic suppression among children with perinatally acquired HIV infection on highly active antiretroviral therapy. Med Care 2005; 43(suppl 9):III15-III22.
13. Warszawski J, Lechenadec J, Faye A, et al. Long-term nonprogression of HIV infection in children: evaluation of the ANRS Prospective French Pediatric Cohort. Clin Infect Dis 2007; 45:785-794.
14. Dormont J. Stratégies d'utilisation des antirétroviraux dans l'infection par le VIH. Paris, France: Flammarion Médecine Sciences Ed, 1997.
15. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH: recommandations du groupe d'expert. Paris, France: Flammarion Médecine Sciences Ed, 2004.
16. Prise en charge medicale des personnes infectées par le VIH: recommandations du groupe d'experts sous la direction du Pr P Yeni. Paris, France: Medecine-Sciences Flammarion Ed, 2008.
17. Sempe M, Rolland-Cachera MF. Etude sequentielle C.E.C.D.E 1953- 1975. Paris, France: Meditions Ed, 2005.
18. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994; 43(RR- 12):1-10.
19. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17):1-19.
20. The European Collaborative Study. Natural history of vertically acquired human immunodeficiency virus 1 infection. Pediatrics 1994; 94:815-819.
21. Blanche S, Newell ML, Mayaux MJ, et al. Morbidity and mortality in European children vertically infected by HIV-1: the French Pediatric HIV Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:442-450.
22. Ministère de l'Education Nationale. Géographie de l'école. No.9, 2005. http://media.education.gouv.fr/file/88/3/1883.pdf.
23. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR; Adolescent Medicine HIV/AIDS Research Network. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003; 157:249-255.
24. Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics 2006; 118:e1745-e1757.
25. Patterson JM,Wall M, Berge J, Milla C. Gender differences in treatment adherence among youth with cystic fibrosis: development of a new questionnaire. J Cyst Fibros 2008; 7:154-164.
26. Kahana SY, Frazier TW, Drotar D. Preliminary quantitative investigation of predictors of treatment non-adherence in pediatric transplantation: a brief report. Pediatr Transplant 2008; 12:656-660.
27. Jullien V, Urien S, Hirt D, et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother 2006; 50:3548-3555.
28. Marhefka SL, Tepper VJ, Brown JL, Farley JJ. Caregiver psychosocial characteristics and children's adherence to antiretroviral therapy. AIDS Patient Care STDS 2006; 20:429-437.
29. Howland LC, Gortmaker SL, Mofenson LM, et al. Effects of negative life events on immune suppression in children and youth infected with human immunodeficiency virus type 1. Pediatrics 2000; 106:540-546.
30. Flynn PM, Rudy BJ, Lindsey JC, et al. Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses 2007; 23:1208-1214.
31. Trocme N, Vaudre G, Dollfus C, Leverger G. Factors impacting on antiretroviral therapy compliance in HIV positive adolescents. Archives de Pédiatrie 2002; 9:1241-1247.
32. Murphy DA, Belzer M, Durako SJ, Sarr M, Wilson CM, Muenz LR; Adolescent Medicine HIV/AIDS Research Network. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 2005; 159:764-770.
33. Ding H, Wilson CM, Modjarrad K, McGwin G Jr, Tang J, Vermund SH. Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2009; 163:1100-1105.
34. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2001; 13:27-40.